These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 30670049)

  • 61. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
    Kim JH; Park HE; Cho NY; Lee HS; Kang GH
    Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CUZD1 is a critical mediator of the JAK/STAT5 signaling pathway that controls mammary gland development during pregnancy.
    Mapes J; Li Q; Kannan A; Anandan L; Laws M; Lydon JP; Bagchi IC; Bagchi MK
    PLoS Genet; 2017 Mar; 13(3):e1006654. PubMed ID: 28278176
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
    Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
    Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibitor-based affinity probes for the investigation of JAK signaling pathways.
    Höfener M; Pachl F; Kuster B; Sewald N
    Proteomics; 2015 Sep; 15(17):3066-74. PubMed ID: 25959371
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I.
    Dong H; Wen C; He L; Zhang J; Xiang N; Liang L; Hu L; Li W; Liu J; Shi M; Hu Y; Chen S; Liu H; Yang X
    J Transl Med; 2024 Aug; 22(1):769. PubMed ID: 39143573
    [TBL] [Abstract][Full Text] [Related]  

  • 69. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
    Sumimoto H; Takano A; Teramoto K; Daigo Y
    PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Decoding LY6G6D in colorectal cancer: Unraveling biomarker potential and therapeutic insights.
    Naqvi M; Abbasi WA; Samma MK; Gabol AA; Innocent C; Iqbal S; Fatima S; Ali K
    Cell Mol Biol (Noisy-le-grand); 2024 Jun; 70(6):14-20. PubMed ID: 38836687
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
    Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
    Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy.
    Huang KC; Ke TW; Lai CY; Hong WZ; Chang HY; Lee CY; Wu CH; Chiang SF; Liang JA; Chen JY; Yang PC; Chen WT; Chuang EY; Chao KSC
    Biomed Pharmacother; 2024 Aug; 177():116958. PubMed ID: 38917760
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer.
    Matsumoto T; Okayama H; Nakajima S; Saito K; Nakano H; Endo E; Kase K; Ito M; Yamauchi N; Yamada L; Kanke Y; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Mimura K; Kono K
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260328
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 75. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
    Ho WW; Gomes-Santos IL; Aoki S; Datta M; Kawaguchi K; Talele NP; Roberge S; Ren J; Liu H; Chen IX; Andersson P; Chatterjee S; Kumar AS; Amoozgar Z; Zhang Q; Huang P; Ng MR; Chauhan VP; Xu L; Duda DG; Clark JW; Pittet MJ; Fukumura D; Jain RK
    Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725151
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.
    Wang X; Fang Y; Liang W; Wong CC; Qin H; Gao Y; Liang M; Song L; Zhang Y; Fan M; Liu C; Lau HC; Xu L; Li X; Song W; Wang J; Wang N; Yang T; Mo M; Zhang X; Fang J; Liao B; Sung JJY; Yu J
    Cancer Cell; 2024 Oct; 42(10):1729-1746.e8. PubMed ID: 39303724
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Loss of JAK1 Drives Innate Immune Deficiency.
    Witalisz-Siepracka A; Klein K; Prinz D; Leidenfrost N; Schabbauer G; Dohnal A; Sexl V
    Front Immunol; 2018; 9():3108. PubMed ID: 30671064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.